Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies

NCT05690581 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors and Hematologic Malignancies

Interventions

DRUG: CM369

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.